Novel Oral Therapeutics for the Treatment of Immunology and Inflammation Diseases

A multinational pharmaceutical company is seeking novel oral drug molecules for immunology and inflammation diseases. The modalities include oral small molecules, protein or RNA degraders, oral peptides, etc. Specifically, our client is most interested in novel oral therapeutics that act on clinically validated targets with biologic drugs in Phase 1 and beyond. 

Approaches of Interest:

• All immunology and inflammation diseases are of interest. Therapeutics that treat asthma, COPD, IPF and IBD are of highest priority
• Modalities of interest include small molecules, peptides, proteins, antibodies, and RNA-based therapeutics that are delivered orally
• Any pathway that has been clinically validated with a biologic therapeutic is of highest interest, e.g. IL-4Ra, TSLP, IgE, etc

Out of Scope:

• Therapeutics that act on targets with existing approved small molecule drugs, e.g. JAK, TYK2, BTK, SIP1
• Natural products
• Repurposed or reformulated drugs
• Projects without an existing functional hit compound showing a clear mechanism of action

Developmental Stages of Interest:

• Opportunities from functional hit to Phase 2 are within scope
• Opportunities with safety and efficacy data are of highest interest

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions that contain information on the target, modality, and characteristics of the therapeutic compound will be prioritised. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.